Ashita Waterston
A5082554609- Cutaneous Melanoma Detection and Management
- Melanoma and MAPK Pathways
- CAR-T cell therapy research
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Surgical Treatments
- Testicular diseases and treatments
- Cancer Immunotherapy and Biomarkers
- Cancer Treatment and Pharmacology
- Immunotherapy and Immune Responses
- Chemotherapy-induced cardiotoxicity and mitigation
- Sarcoma Diagnosis and Treatment
- Ovarian cancer diagnosis and treatment
- Viral-associated cancers and disorders
- Gastric Cancer Management and Outcomes
- Synthesis of Tetrazole Derivatives
- Cancer Genomics and Diagnostics
- HIV/AIDS drug development and treatment
- Angiogenesis and VEGF in Cancer
- Monoclonal and Polyclonal Antibodies Research
- T-cell and B-cell Immunology
- HER2/EGFR in Cancer Research
- Pancreatic and Hepatic Oncology Research
- Chemotherapy-induced organ toxicity mitigation
- Cancer Research and Treatments
- Lymphoma Diagnosis and Treatment
Beatson West of Scotland Cancer Centre
2015-2024
NHS Greater Glasgow and Clyde
2018-2024
National Health Service
2023
Association for Language Learning
2015
Gartnavel General Hospital
2015
Imperial College London
2004-2005
Cancer Research UK
2005
Chelsea and Westminster Hospital
2004
Hammersmith Hospital
2004
Institute of Rheumatology
1999
6 months of oxaliplatin-containing chemotherapy is usually given as adjuvant treatment for stage 3 colorectal cancer. We investigated whether would be non-inferior to the usual treatment.The SCOT study was an international, randomised, phase 3, non-inferiority trial done at 244 centres. Patients aged 18 years or older with high-risk II and III cancer underwent central randomisation minimisation centre, choice regimen, sex, disease site, N stage, T starting dose capecitabine. were assigned...
Bevacizumab, a monoclonal antibody that targets VEGF, has shown restricted activity in patients with advanced melanoma. We aimed to assess the role of bevacizumab as adjuvant treatment for resected melanoma at high risk recurrence. report results from preplanned interim analysis.We did multicentre, open-label, randomised controlled phase 3 trial 48 centres UK between July 18, 2007, and March 29, 2012. Patients aged 16 years or older American Joint Committee on Cancer stage (AJCC) IIB, IIC,...
Purpose Immunosuppression induced by HIV-1 increases the risk of developing non-Hodgkin's lymphoma (NHL). We measured influence immunologic factors and highly active antiretroviral therapy (HAART) on this risk. As there are no data demonstrating that specific regimens effective at protecting from NHL, we compared different HAART regimens. Patients Methods The protective effect regimens, containing protease inhibitors (PI) and/or non-nucleoside reverse transcriptase (NNRTIs) development NHL...
Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab melanoma patients at high risk recurrence.Patients with resected AJCC stage IIB, IIC and III cutaneous were randomised receive either (7.5 mg/kg i.v. 3 weekly for 1 year) or standard observation. The primary end point was detection an 8% difference 5-year overall (OS) rate; secondary points included...
Rapidly accelerated fibrosarcoma B-type (BRAF) and mitogen-activated extracellular signal-regulated kinase (MEK) inhibitors have revolutionized treatment for patients with BRAF-mutated melanoma. Although left ventricular systolic dysfunction associated these therapies has been reported in clinical trials, the real-world incidence is poorly defined, as are risk factors its development.This study sought to characterize incidence, time course, cancer therapy-related cardiac (CTRCD) melanoma...
The timing of adjuvant chemotherapy after surgery for colorectal cancer and its association with long-term outcomes have been investigated in national cohort studies, no consensus on the optimal time from to chemotherapy.
Not all patients respond equally to neoadjuvant chemoradiotherapy (nCRT), with subsequent effects on survival. The systemic inflammatory response has been shown predict long-term outcomes in colorectal cancer. current study examined the association between inflammation and nCRT rectal cancer.Between 1999 2010, who underwent were identified. Serum measurements of hemoglobin, C-reactive protein, albumin, modified Glasgow prognostic score (mGPS), differential white cell counts obtained before...
Oxaliplatin and fluoropyrimidine chemotherapy administered over 6 months is the standard adjuvant regimen for patients with high-risk stage II or III colorectal cancer. However, associated cumulative toxicity, characterised by chronic often irreversible neuropathy. To assess efficacy of 3-month versus 6-month cancer to compare health-related quality life cost-effectiveness durations. An international, randomised, open-label, non-inferiority, Phase III, parallel-group trial. A total 244...
Cisplatin-based chemotherapy increases the risk of cardiovascular and renal disease.We aimed to define time course, pathophysiology, approaches prevent disease associated with cisplatin-based chemotherapy.Two cohorts patients a history testicular cancer (n = 53) were recruited. Cohort 1 consisted 27 men undergoing treatment with: 1) surveillance; 2) 2 cycles bleomycin, etoposide, cisplatin (BEP) (low-intensity cisplatin); or 3) 3 4 BEP (high-intensity cisplatin). Endothelial function...
The Short Course Oncology Therapy (SCOT) study is an international, multicentre, non-inferiority randomised controlled trial assessing the efficacy, toxicity, and cost-effectiveness of 3 months (3 M) versus usually given 6 (6 adjuvant chemotherapy in colorectal cancer. In total, 6088 patients with fully resected high-risk stage II or III cancer were followed up for 3–8 years. within-trial analysis from a UK health-care perspective presented using resource use data, quality life (EQ-5D-3L),...
TNF is a proinflammatory cytokine involved in the pathogenesis of chronic inflammatory diseases, but also metastasis certain types cancer. In terms therapy, targeted by anti-TNF neutralising monoclonal antibodies or soluble receptors. Recently, novel strategy based on generation self (TNF autovaccination) has been developed. We have previously shown that autovaccination successfully generates high antibody titres, blocks and ameliorates collagen-induced arthritis DBA/1 mice. this study, we...
To assess stoma-related complications of colorectal cancer patients undergoing surgery with curative intent who received adjuvant chemotherapy compared to those underwent alone.A retrospective analysis a prospectively maintained clinical audit database was completed.Patients for the formation stoma (end ileostomy, loop end colostomy) between 1999 and 2011 at single hospital in Lanarkshire, United Kingdom. Patients neo-adjuvant were excluded. Two hundred twenty-two comprised study sample; 130...
3502 Background: Six months of oxaliplatin-based treatment has been the mainstay adjuvant chemotherapy for colorectal cancer last 13 years. Neurotoxicity from oxaliplatin is cumulative, dose limiting, and potentially irreversible. A shorter duration would save patients significant toxicity/time substantially reduce costs drug, its administration, adverse effects. Methods: SCOT a non-inferiority randomised study designed to determine whether 3 with OxMdG or Xelox (physician/patient choice) in...
1034 Background: Immunosuppression induced by the human immunodeficiency virus (HIV) leads to an increased risk of non Hodgkin's lymphoma (NHL). We measured influence immunological factors and highly active antiretroviral therapy (HAART) regimes on this risk. As there are few data demonstrating that nucleoside reverse transcriptase inhibitors (NNRTI) can protect from AIDS-defining illnesses, we compared different HAART regimens. Methods: The protective effect regimens, containing protease...